Jane L Burns, MD

Professional History

Board Certified:

Pediatric Infectious Diseases

Medical/Professional School:

University of Washington, Seattle

Residency:

University of Washington, Seattle, Pediatrics

Fellowship:

University of Washington, Seattle, Pediatric Infectious Disease

Clinical Interests:

Cystic fibrosis microbiology, bacterial antibiotic resistance, bone and joint infections

Description of Research:

My primary area of research for many years has been cystic fibrosis (CF) microbiology, including antibiotic resistance and bacterial pathogenesis. My studies have used both in vitro and in vivo models of infection. Novel methods of in vitro susceptibility testing have been established, including testing drug activity against bacteria grown in biofilms and examining drug bioactivity in the presence of CF sputum. I have worked with both primary CF cells and immortalized cell lines in tissue culture to examine bacterial pathogenesis including attachment, invasion and apoptosis. In vivo experiments use a mouse model of chronic bacterial infections with Pseudomonas aeruginosa and Burkholderia cepacia complex.

My recent work is examining the phenotypic and genotypic adaptations of both organisms to growth within the CF airway. I frequently collaborate with clinical and basic science CF researchers at Seattle Children's Hospital and the University of Washington. In addition, I direct the Center for CF Microbiology at Seattle Children's Hospital, which is a core laboratory for the CF Foundation Therapeutics Development Network.

Key Publications:

Gibson, R.L., Emerson, J., Mayer-Hamblett, N., Burns, J.L., McNamara, S., Accurso, F.J., Konstan, M.W., Chatfield, B.A., Retsch-Bogart, G., Waltz, D.A., Acton, J., Zeitlin, P., Hiatt, P., Moss, R., Williams, J., and Ramsey, B.W. Duration of treatment effect after tobramycin solution for inhalation in young children with cystic fibrosis. Pediatr Pulmonol 42(7):610-623, 2007.

Ernst, R.K., Moskowitz, S.M., Emerson, J.C., Kraig, G.M., Adams, K.N., Harvey, M.D., Ramsey, B., Speert, D., Burns, J.L., and Miller, S.I. Unique lipid A modifications in Pseudomonas aeruginosa isolated from the airways of patients with cystic fibrosis. J Infect Dis 196(7);1088-1092, 2007.

Retsch-Bogart, G.Z., Burns, J.L., Otto, K.L., Liou, T.G., McCoy, K., Oermann, C., and Gibson, R.L. A phase 2 study of aztreonam lysine for inhalation to treat patients with cystic fibrosis and Pseudomonas aeruginosa infection. Pediatr Pulmonol 43(1);47-58, 2008 (non-NIH).

Hayden, H.S., Gillett, W., Saenphimmachak, C., Lim, R., Zhou, Y., Jacobs, M.A., Chang, J., Rohmer, L., D?Argenio, D.A., Palmieri, A., Levy, R., Haugen, E., Wong, G.K., Brittnacher, M.J., Burns, J.L., Miller, S.I., Olson, M.V., and Kaul, R. Large insert genome analysis (LIGAN) technology detects structural variation in Pseudomonas aeruginosa clinical strains from cystic fibrosis patients. Genomics 91(6):530-537, 2008 (non-NIH).

Mena, A., Smith, E.E., Burns, J.L., Speert, D.P., Moskowitz, S., Perez, J.L., and Oliver, A. Genetic adaptation of Pseudomonas aeruginosa to the airways of cystic fibrosis patients is catalyzed by hypermutation. J Bacteriol 190:7910-7917, 2008 (non-NIH).

Hoffman, L., Miller, S.I., Ramsey, B., and Burns, J.L. Pseudomonas aeruginosa lasR mutants are associated with cystic fibrosis lung disease progression. J Cyst Fibros 8:66-70, 2009 (non-NIH).

Honors & Awards:

2004-06, 2008: Seattle Magazine Top Doc

2006-08: Seattle Metropolitan Magazine Top Doctor